logo

Centre de Preuves en Dermatologie Best practice guidelines

Guidelines cold urticaria Updated on Sep 24

Responsibility

The information provided by this website comes from sources deemed reliable. However, the Société Française de Dermatologie recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The Société Française de Dermatologie cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

Omalizumab

Back to decision-making tree Print last updated on 26/09/2024

Despite the low level of evidence, the working group recommends using omalizumab in cases of cold urticaria resistant to quadruple doses of anti-H1 antihistamines.

The working group recommends initially prescribing concomitant second-generation anti-H1 antihistamines at quadruple doses.

The recommended initial dose of omalizumab is 150 mg every 4 weeks. If there is no improvement after 12 weeks (UCT < 12/16), the dose can be increased to 300 mg every 4 weeks.

The working group reminds that omalizumab is only approved for chronic spontaneous urticaria from the age of 12.

The recommendations for the pediatric population are the same, although omalizumab is only approved for asthma from the age of 6 and for chronic spontaneous urticaria from the age of 12.

  • Was this article helpful to you?

  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.

➜ Associated measures

Centre de Preuves en Dermatologie Centre de Preuves en Dermatologie logo
Work
10 cité Malesherbes
75009Paris
Île-de-France
FRANCE
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86
centredepreuvesdermato@sfdermato.org